Intellipharmaceutics International Stock Cash Per Share
IPCIFDelisted Stock | USD 0.04 0.00 0.00% |
Intellipharmaceutics International fundamentals help investors to digest information that contributes to Intellipharmaceutics' financial success or failures. It also enables traders to predict the movement of Intellipharmaceutics OTC Stock. The fundamental analysis module provides a way to measure Intellipharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intellipharmaceutics otc stock.
Intellipharmaceutics |
Intellipharmaceutics International OTC Stock Cash Per Share Analysis
Intellipharmaceutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Intellipharmaceutics International has a Cash Per Share of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The cash per share for all United States stocks is 100.0% higher than that of the company.
Intellipharmaceutics Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intellipharmaceutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Intellipharmaceutics could also be used in its relative valuation, which is a method of valuing Intellipharmaceutics by comparing valuation metrics of similar companies.Intellipharmaceutics is currently under evaluation in cash per share category among its peers.
Intellipharmaceutics Fundamentals
Return On Asset | -0.98 | ||||
Operating Margin | (106.06) % | ||||
Current Valuation | 4.47 M | ||||
Shares Outstanding | 33.09 M | ||||
Shares Owned By Insiders | 1.70 % | ||||
Shares Owned By Institutions | 11.09 % | ||||
Number Of Shares Shorted | 714 K | ||||
Price To Earning | (0.50) X | ||||
Price To Sales | 66.19 X | ||||
Gross Profit | 1.4 M | ||||
EBITDA | (4.45 M) | ||||
Net Income | (5.15 M) | ||||
Cash And Equivalents | 79.65 K | ||||
Total Debt | 2.01 M | ||||
Debt To Equity | 165.20 % | ||||
Current Ratio | 0.05 X | ||||
Book Value Per Share | (0.31) X | ||||
Cash Flow From Operations | (2.46 M) | ||||
Short Ratio | 0.39 X | ||||
Earnings Per Share | (0.16) X | ||||
Target Price | 25.0 | ||||
Number Of Employees | 11 | ||||
Beta | 1.0 | ||||
Market Capitalization | 2.02 M | ||||
Total Asset | 2.1 M | ||||
Retained Earnings | (86.55 M) | ||||
Working Capital | (5.62 M) | ||||
Current Asset | 1.41 M | ||||
Current Liabilities | 7.02 M | ||||
Z Score | -65.8 | ||||
Net Asset | 2.1 M |
About Intellipharmaceutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intellipharmaceutics International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellipharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellipharmaceutics International based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin | |
ADA | Cardano | |
XRP | XRP |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |